The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older. One of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/V0ZpuAR
No comments:
Post a Comment